header logo en

About 10-for-IO


The 10-for-IO website is a project of the International Kidney Cancer Coalition (ikcc.org). The purpose of this website is to provide a central resource for patient organisations to access information about immuno-oncology (also referred to as "IO") specifically as it applies to renal cell carcinoma.

This project was conceived by the Board of Directors of the International Kidney Cancer Coalition to address the many questions patients around the world are asking, to address misinformation in the media and unmoderated forums, and to provide a medically-reviewed source of information in straightforward patient language.

Medical sources are cited throughout. New medical content for this website has been written by volunteers and medically reviewed by a minimum of two Medical or Uro-Oncologists who have in-depth knowledge of both kidney cancer and immuno-oncology in their respective countries.

The 10-for-IO website has already been recognized as an important step forward in patient engagement in an area of emerging scientific discovery. Deans of the University Medical Center Utrecht (www.umcutrecht.nl) fully support and endorse this patient-led initiative.

Questions and comments on this website are most welcome. Please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Please note that this website accepts no advertising.


The IKCC Board would specifically like to thank:
Dr. Craig Gedye, Australia
Prof. Dr. Viktor Grünwald, Germany
Dr. Niven Mehra, UK
Dr. Rachel Giles, Chair IKCC, the Netherlands 
Deborah Maskens, Vice-Chair IKCC, Canada
Dr. Saskia Gooskens, the Netherlands



Seed funding for this website concept was received by the IKCC from Bristol-Myers Squibb (BMS) in response to their Request for Proposals to International Organizations. Subsequently the 10-for-IO project has been supported by the IKCC (for a complete list of sponsors of the IKCC click here), and by the volunteer hours of Medical Experts in the U.K., Germany, Australia, and The Netherlands, who have reviewed text and provided comments. The health science communications firm Oxford PharmaGenesis Ltd in the UK provided guidance and editing services for usability. In addition, Affiliate Organisations of the IKCC (click here) have reviewed the website for applicability to their country’s patient needs. A grant supporting translations of this website was supported by Novartis in 2016.